Development of human thrombin production at National Blood Centre, Thai Red Cross Society

Authors

  • Thongyip Nakdaeng National Blood Centre, Thai Red Cross Society
  • Anawat Chernkwansri National Blood Centre, Thai Red Cross Society
  • Supaporn Praput National Blood Centre, Thai Red Cross Society
  • Thantawat Theeranan Department of Biotechnology, Faculty of Science, Mahidol University
  • Wadee Rungpradubvong National Blood Centre, Thai Red Cross Society

Keywords:

Human thrombin, Production, Purification, Human plasma, ทรอมบินของมนุษย์, การผลิต, การทำให้บริสุทธิ์, พลาสมาของมนุษย์

Abstract

Abstract:

Introduction: Human thrombin (HT) has been widely used in hemostatic products and used as an active ingredient to produce fibrin sealant or fibrin glue. Fibrin sealant was produced by National Blood Centre, Thai Red Cross Society (NBC, TRCS) since 1997 using imported HT. It was clinically applied in many surgeries such as dental and heart procedures. However, since 2010, the manufacturer has denied to supply the product. As a result, fibrin sealant production was terminated. The development of HT from local plasma was initiated in phase I during 2016-2020 in order to utilize proteins in plasma to maximize their benefits in patient treatment. Objective: This study aims to develop a process for producing HT from plasma at the NBC, TRCS instead of importing from abroad which is expensive. Materials and Methods: The production of thrombin started with prothrombin complex (PTC) separation, where pooled cryo-removed plasma (CRP) was processed with DEAE Sephadex resin and eluted to obtain crude PTC before converting PTC to thrombin by glycine, calcium chloride, and pH control. Solvent detergent (SD) treatment was performed to ensure viral safety before thrombin purification using SP Sephadex column chromatography and nanofiltration. The prothrombin and purified thrombin were analyzed for activity and purity using coagulation assays, spectrophotometry, gas chromatography, and SDS-PAGE. Results: HT production from three 20 L of CRP batches yielded titers of 12,665, 11,143 and 12,727 IU/mL, with specific activities of 1,550, 1,450, and 1,509 IU/mg, respectively. SD residues were within acceptable limits in 2 batches, and SDS-PAGE showed no other protein bands post-purification. Scaling up to 40 L of CRP for two lots produced results consistent with the 20 L batches in terms of thrombin titer, specific activity, and SD residues. Conclusion: NBC, TRCS developed scalable HT from plasma production meeting the criteria for medical and research applications. 

Downloads

Download data is not yet available.

References

Isarangkura P, Chiewsilp P, Chuansumrit A, Suwannuraks M, Keorochana SB, Attanawanich S, et al. Low cost locally prepared fibrin glue for clinical applications: reported of 145 cases. Committee of Bangkok International Hemophilia Training Center. J Med Assoc Thai. 1999;82 (suppl 1):S49-56.

Suwannuraks M, Chuansmrit A, Sriudomporn N. The use of fibrin glue as an operative sealant in dental extraction in bleeding disorder patients. Haemophilia. 1999;5:106-8.

Rock G, Neurath D, Semple E, Harvey M, Freedman M. Preparation and characterization of human thrombin for use in a fibrin glue. Transfus Med. 2007;17:187–91.

Fernández-Vega-Cueto L, Persinal-Medina M, Vázquez N, Chacón M, Alfonso-Bartolozzi B, Alonso-Alonso S, et al. A simple, safe, and effective method for preparing autologous bio-based fibrin glue for ophthalmic use. Pharmaceutics. 2022;14:2325.

Kumar Vijay, Chapman John R. Whole blood thrombin: development of a process for intra-operative production of human thrombin. J Extra Corpor Technol. 2007;39:18–23.

Pinnopmanee S. Viral inactivation and viral removal for plasma products. J Transfus Med. 2019;29:145–52.

Burnouf T, Radosevich M, Goubran HA, Willkommen H. Place of nanofiltration for assuring viral safety of biologicals. Curr Nanosci. 2005;1:189–201.

Ministry of Health L and W. Japanese Pharmacopoeia. 17th ed. Ministry of Health, Labour and Welfare; 2016.

Fenton JW, Campbell WP, Harrington JC, Miller KD. Large-scale preparation and preliminary characterization of human thrombin. BBA Prot St. 1971;229:26–32.

Aizawa P, Winge S, Karlsson G. Large-scale preparation of thrombin from human plasma. Thromb Res. 2008;122:560–7.

European Directorate for the Quality of Medicines & HealthCare. Fibrin sealant kit. In: European Pharmacopoeia. 11th ed. Strasbourg Cedex: Council of Europe; 2022. p. 2763-5.

Cytiva. HiPrepTM CM FF 16/10, HiPrep DEAE FF 16/10, HiPrep Q FF 16/10, HiPrep SP FF 16/10, HiPrep Q HP 16/10, and HiPrep SP HP 16/10 prepacked columns: instructions for use. Vol. 28941323 AE V:4. 2020.

Kaetsu H, Mizuguchi J, Hamamoto T, Kamimura K, Yoshida Y, Nakagaki T, et al. Large-scale preparation of human thrombin: polyethylene glycol potentiates the Ffctor Xa-mediated activation of prothrombin. Thromb Res. 1998;90:101–9.

Ngai PK, Chang JY. A novel one-step purification of human α-thrombin after direct activation of crude prothrombin enriched from plasma. Biochem J. 1991;280:805–8.

Downloads

Published

2025-05-20

Issue

Section

นิพนธ์ต้นฉบับ (Original article)